Preferred Pharmaceuticals, Inc. is recalling 1,190 bottles of Clindamycin Hydrochloride Capsules, USP (300mg), which were manufactured by Glenmark Pharmaceuticals Limited. The recall was initiated due to deviations from current Good Manufacturing Practice (cGMP) requirements. The affected product is packaged in 30-count bottles and includes nine specific lot numbers with an expiration date of July 31, 2026.
Deviations from manufacturing standards can compromise the quality and consistency of the medication. This may lead to the drug being less effective than intended or possessing unexpected quality issues, though no specific injuries have been reported.
You have 2 options:
Manufactured by Glenmark Pharmaceuticals Limited; repackaged/distributed by Preferred Pharmaceuticals, Inc.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.